BioStem Technologies, Inc. (OTCMKTS:BSEM) Sees Significant Increase in Short Interest

BioStem Technologies, Inc. (OTCMKTS:BSEM) was the target of a large increase in short interest in October. As of October 31st, there was short interest totalling 115,100 shares, an increase of 22.3% from the October 15th total of 94,100 shares. Based on an average daily volume of 124,800 shares, the short-interest ratio is presently 0.9 days.

BioStem Technologies Stock Performance

Shares of OTCMKTS:BSEM traded down 5.95 during midday trading on Friday, reaching 17.41. 257,100 shares of the company’s stock traded hands, compared to its average volume of 33,599. The company has a fifty day simple moving average of 13.43 and a two-hundred day simple moving average of 10.69. BioStem Technologies has a 1 year low of 2.34 and a 1 year high of 28.26. The company has a market cap of $289.35 million, a P/E ratio of 25.60 and a beta of -0.36.

BioStem Technologies (OTCMKTS:BSEM) last announced its quarterly earnings data on Tuesday, November 12th. The company reported 0.32 earnings per share (EPS) for the quarter, beating the consensus estimate of 0.31 by 0.01. The company had revenue of 82.56 million during the quarter, compared to analysts’ expectations of 78.22 million. As a group, research analysts forecast that BioStem Technologies will post 1.13 EPS for the current fiscal year.

BioStem Technologies Company Profile

BioStem Technologies, Inc, a life sciences corporation, focuses on discovering, developing, and producing pharmaceutical and regenerative medicine products and services. It develops various biologic stem cell based alternative products, as a treatment for ailments, such as joint pain, tendon and ligament injuries, neurodegenerative, and autoimmune diseases.